4m
Hosted on MSNGilead’s lenacapavir applications for HIV gain EMA validationGilead Sciences has announced the European Medicines Agency’s (EMA) validation for a parallel accelerated review of ...
A groundbreaking injectable designed to curb the global spread of HIV is now at risk of being delayed due to Donald Trump's ...
Morgan Stanley expects the FDA to approve Gilead Sciences (NASDAQ:GILD)' Lenacapavir (LEN) for HIV prevention (PrEP) on or before its June 19 PDUFA date, a move that the bank believes could drive ...
Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But without US foreign aid dollars, its delivery to millions worldwide is under ...
7d
GlobalData on MSNGilead’s lenacapavir moves closer to FDA approval for HIV PrEP useThe US Food and Drug Administration (FDA) has accepted Gilead’s new drug application (NDA) for lenacapavir and set a ...
Missed KHOU 11+’s live Q&A on injectable PrEP? Watch on demand as experts discuss this HIV prevention breakthrough and answer ...
Foster City, California Tuesday, February 25, 2025, 16:00 Hrs [IST] ...
6d
News Medical on MSNNew HIV therapy lenacapavir shows high efficacy in Ugandan populationA multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application submissions for lenacapavir for human immunodeficiency virus (HIV) prevention.
A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...
Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results